Allscripts (NASDAQ:MDRX) has been assigned a consensus recommendation of “Hold” from the twenty ratings firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.58.
MDRX has been the subject of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price objective on shares of Allscripts in a research report on Monday, January 8th. Maxim Group reissued a “buy” rating and issued a $20.00 price objective on shares of Allscripts in a research report on Tuesday, January 9th. BidaskClub cut Allscripts from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Royal Bank of Canada set a $19.00 target price on Allscripts and gave the stock a “buy” rating in a research report on Thursday, January 11th. Finally, Zacks Investment Research cut Allscripts from a “hold” rating to a “sell” rating in a research report on Friday, January 12th.
MDRX opened at $12.02 on Thursday. Allscripts has a 1-year low of $10.78 and a 1-year high of $16.13. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.97 and a quick ratio of 0.97. The company has a market capitalization of $2,144.33, a PE ratio of 25.57, a price-to-earnings-growth ratio of 1.55 and a beta of 1.23.
Allscripts (NASDAQ:MDRX) last posted its quarterly earnings data on Thursday, February 15th. The software maker reported $0.18 earnings per share for the quarter, meeting the consensus estimate of $0.18. Allscripts had a positive return on equity of 7.36% and a negative net margin of 10.88%. The company had revenue of $547.00 million during the quarter, compared to analysts’ expectations of $524.05 million. During the same period in the prior year, the business earned $0.14 earnings per share. Allscripts’s revenue for the quarter was up 27.5% compared to the same quarter last year. sell-side analysts predict that Allscripts will post 0.56 EPS for the current year.
In other Allscripts news, EVP Brian Farley sold 5,000 shares of Allscripts stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. Following the completion of the transaction, the executive vice president now directly owns 240,672 shares of the company’s stock, valued at $3,304,426.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Richard J. Poulton sold 15,000 shares of Allscripts stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $13.53, for a total value of $202,950.00. Following the transaction, the president now directly owns 505,920 shares of the company’s stock, valued at $6,845,097.60. The disclosure for this sale can be found here. 0.75% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of MDRX. Redmile Group LLC bought a new position in shares of Allscripts during the fourth quarter valued at $25,762,000. Community Trust & Investment Co. bought a new position in shares of Allscripts during the fourth quarter valued at $8,693,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Allscripts during the fourth quarter valued at $8,160,000. Dalton Greiner Hartman Maher & Co. lifted its holdings in shares of Allscripts by 18.4% during the fourth quarter. Dalton Greiner Hartman Maher & Co. now owns 2,990,902 shares of the software maker’s stock valued at $43,518,000 after acquiring an additional 465,037 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Allscripts by 85.6% during the third quarter. Ameriprise Financial Inc. now owns 952,925 shares of the software maker’s stock valued at $13,559,000 after acquiring an additional 439,489 shares during the period.
TRADEMARK VIOLATION WARNING: This piece was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/04/15/allscripts-mdrx-receives-16-58-consensus-pt-from-analysts.html.
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.